cellular
lipid
known
play
import
role
life
cycl
mani
envelop
virus
lipid
major
constitu
cell
membran
surpris
implic
cell
entri
mechan
mani
virus
human
immunodefici
viru
hiv
epsteinbarr
viru
ebv
coronaviru
semliki
forest
viru
sfv
name
besid
involv
viral
entri
membran
level
cellular
lipid
also
essenti
mani
intracellular
process
viral
protein
posttransl
fatti
acid
modif
eg
acyl
myristyl
palmitoyl
prenyl
also
play
import
role
envelop
viru
assembl
protein
traffick
lipid
critic
biolog
envelop
virus
virus
modul
hostcel
lipid
metabol
advantag
downregul
lipid
synthesi
howev
recent
report
demonstr
involv
lipid
cell
biolog
nonenvelop
doublestrand
rna
viru
rotaviru
well
rotaviru
belong
famili
reovirida
lead
etiolog
agent
caus
viral
gastroenter
human
anim
parashar
et
al
estim
mean
rang
death
rotaviru
diseas
worldwid
per
annum
role
lipid
rotavir
entri
specif
lipid
bind
viral
protein
associ
infecti
virion
rotavir
protein
within
lipid
raft
assembl
releas
document
noteworthi
among
studi
one
clearli
underlin
role
lipid
raft
rotaviru
biolog
demonstr
viral
protein
well
triplelay
infecti
particl
associ
raft
cultur
cell
experiment
infect
anim
assembl
viral
particl
occur
extraer
event
recent
delma
et
al
report
distinct
differ
rafttyp
membran
microdomain
cell
anoth
cell
line
monkey
kidney
epitheli
cell
two
commonli
use
cell
line
studi
rotaviru
replic
vitro
present
studi
demonstr
effect
cholesterol
deplet
rotaviru
titer
assembl
cell
util
lovastatin
inhibit
hmg
coa
reductas
ratelimit
enzym
cholesterol
biosynthesi
analysi
reveal
drug
treatment
appar
reduc
rotaviru
titer
cell
transmiss
electron
microscopi
show
cholesterollow
drug
profound
effect
viru
assembl
result
accumul
defect
emptylook
particl
insid
cell
cell
atcc
manassa
va
routin
cultur
dulbecco
modifi
eagl
medium
dmem
mediatech
herndon
va
contain
fetal
bovin
serum
fb
hyclon
logan
ut
mm
lglutamin
mediatech
herndon
va
iuml
penicillin
streptomycin
mediatech
inc
herndon
va
simian
rotaviru
atcc
manassa
va
propag
cell
describ
previous
commerci
avail
lovastatin
mevinolin
sigma
chemic
st
loui
mo
use
present
studi
mm
stock
solut
drug
prepar
ethanol
activ
describ
previous
prior
infect
cell
left
untreat
treat
drug
initi
complet
dmem
medium
h
follow
addit
h
incub
mevinolin
constitut
serumfre
medium
viru
infect
carri
describ
previous
briefli
viru
activ
typev
acetyl
trypsin
deriv
bovin
pancrea
sigma
chemic
st
loui
mo
min
overlaid
confluent
cell
min
follow
initi
viru
bind
inoculum
remov
fresh
serumfre
medium
contain
mevinolin
ad
incub
h
trypsin
includ
serumfre
medium
enabl
moder
slow
infect
greater
proport
cell
monolay
recov
h
cell
viabil
two
group
estim
use
trypan
blue
dye
exclus
method
cellular
cholesterol
content
estim
use
commerci
avail
colorimetr
kit
per
manufactur
instruct
roch
indianapoli
usa
viral
titer
estim
fluoresc
focu
assay
ffa
enumer
number
fluoresc
cell
focu
unit
fcfu
per
well
describ
previous
briefli
rotavirusinfect
cell
triplic
clarifi
centrifug
min
follow
initi
viru
bind
inoculum
remov
fresh
serumfre
medium
ad
incub
continu
h
ffa
cell
wash
phosphatebuff
salin
pb
fix
icecold
aceton
min
infect
cell
immunostain
guinea
pig
antirotaviru
antibodi
detect
secondari
incub
goat
antiguineapig
fitclabel
antibodi
vector
burlingam
ca
slide
mount
antifad
mount
medium
vector
burlingam
ca
foci
infect
cell
count
invert
nikon
fluoresc
microscop
model
eclips
nikon
usa
mock
rotavirusinfect
cell
wash
pb
lysat
prepar
ripa
buffer
mm
nacl
triton
sodium
deoxychol
sd
mm
tri
ph
per
previou
protocol
protein
concentr
lysat
estim
use
commerci
avail
kit
base
bradford
assay
biorad
lab
hercul
ca
sampl
volum
equival
load
resolv
sodium
dodecyl
polyacrylamid
gel
electrophoresi
protein
transfer
polyvinyliden
difluorid
pvdf
membran
millipor
usa
viral
protein
detect
use
antibodi
rotaviru
protein
incub
secondari
horseradishperoxidaselabel
antispeci
igg
antibodi
chemicon
temecula
ca
follow
enhanc
chemiluminesc
signal
detect
pierc
usa
immunoblot
also
probe
rabbit
polyclon
anticatalas
antibodi
biomol
plymouth
meet
pa
detect
cellular
catalas
level
housekeep
marker
ensur
equal
protein
load
lane
rtpcr
perform
rna
extract
viral
particl
well
infect
cell
per
previou
protocol
briefli
duplic
set
flask
contain
cell
treat
without
lovastatin
infect
rotaviru
follow
infect
one
set
flask
use
extract
rna
infect
cell
wherea
set
use
first
isol
viru
particl
infect
cell
extract
rna
purifi
particl
viru
particl
extract
infect
cell
repeat
clarifi
centrifug
min
viru
particl
supernat
pellet
centrifug
sucros
cushion
beckman
rotor
min
rna
extract
use
rnastat
teltest
inc
friendswood
tx
describ
previous
rtpcr
perform
detect
level
gene
segment
code
one
rotaviru
structur
protein
nonstructur
protein
use
appropri
pair
primer
rna
level
semiquantit
endpoint
dilut
method
rna
segment
amplifi
use
set
forward
revers
primer
wherea
gene
amplifi
use
set
previous
publish
primer
tem
analysi
perform
rotavirusinfect
cell
analyz
effect
lipidlow
drug
rotaviru
assembl
visual
particl
morpholog
previous
describ
briefli
virusinfect
cell
without
mevinolin
incub
h
wash
pb
trypsin
cell
pellet
fix
h
paraformaldehyd
sodium
cacodyl
buffer
ph
sampl
subsequ
store
pb
process
end
cell
postfix
osmium
tetroxid
dehydr
grade
alcohol
embed
epoxi
resin
thin
section
stain
uranyl
acet
lead
citrat
examin
zeiss
em
omega
electron
microscop
cell
treat
without
lovastatin
least
h
prior
infect
anoth
h
postinfect
hpi
test
cell
viabil
report
earlier
trypan
blue
stain
reveal
signific
differ
cell
viabil
drugtreat
untreat
cell
cellular
cholesterol
analysi
reveal
lovastatintr
cell
undergo
reduct
cholesterol
level
compar
normal
cell
establish
drug
produc
desir
cholesterolreduc
effect
concentr
without
significantli
affect
cell
viabil
rotavir
titer
variou
time
point
estim
ffa
timecours
analysi
reveal
rotavir
titer
compar
normal
drugtreat
cell
earli
time
point
h
suggest
reduct
initi
infect
due
lovastatin
treatment
fig
howev
h
reduct
viral
titer
two
log
observ
lovastatintr
cell
compar
normal
cell
fig
analyz
whether
lovastatininduc
reduct
viral
titer
due
reduct
viral
translat
viral
protein
level
compar
rotavirusinfect
normal
lovastatintr
cell
immunoblot
analysi
reveal
viral
protein
level
repres
unchang
earlier
time
point
hpi
howev
hpi
level
increas
multifold
compar
protein
level
normal
rotavirusinfect
cell
fig
level
catalas
protein
uniform
well
indic
equal
protein
concentr
lane
fig
rtpcr
analysi
indic
mrna
level
gene
segment
within
infect
cell
remain
unchang
drugtreat
normal
cell
hpi
fig
howev
mrna
gene
purifi
particl
subject
rtpcr
result
indic
substanti
decreas
viral
rna
level
particl
deriv
drugtreat
cell
ensur
reproduc
mrna
level
addit
rotaviru
gene
segment
test
well
rtpcr
sinc
result
gene
gene
level
ident
rtpcr
analysi
find
present
represent
analysi
fig
given
result
far
free
viral
protein
abundantli
synthes
drugtreat
cell
viru
infect
titer
decreas
hypothes
proper
viral
assembl
affect
drug
treatment
test
hypothesi
perform
transmiss
electron
microscop
analysi
rotavirusinfect
cell
treat
without
lovastatin
treatment
analysi
indic
untreat
cell
produc
larg
extent
normal
viru
particl
electrondens
core
fig
howev
drugtreat
cell
rel
much
lower
number
normal
viru
particl
increas
number
emptylook
particl
lack
characterist
electrondens
core
fig
suggest
defect
viru
assembl
empti
particl
uniformli
size
closer
size
triplelay
rotaviru
particl
minu
spike
rule
possibl
empti
structur
could
cellular
vesicl
although
previou
report
demonstr
lipid
deplet
affect
rotavir
protein
target
particl
assembl
bee
support
situ
visual
evid
order
gain
quantit
estim
observ
differ
viru
assembl
hpi
drugtreat
control
group
electron
micrograph
area
contain
popul
particl
taken
random
per
cell
micrograph
print
magnif
approxim
code
blind
studi
viral
particl
count
classifi
total
particl
count
micrograph
normal
cell
dens
core
lack
dens
core
lovastatintr
cell
total
particl
count
micrograph
dens
core
emptylook
particl
lack
electrondens
core
clearli
demonstr
lovastatintr
cell
contain
higher
proport
aberr
viru
particl
control
group
present
studi
demonstr
cholesterol
deplet
lovastatin
treatment
result
defect
rotaviru
particl
assembl
cell
concentr
lovastatin
use
present
studi
concurr
previous
publish
report
result
trypan
blue
cell
viabil
assay
reveal
signific
differ
cell
viabil
normal
drugtreat
cell
suggest
drug
advers
affect
cell
viabil
concentr
use
well
establish
lovastatin
reduc
intracellular
cholesterol
level
cellular
cholesterol
requir
rotaviru
infect
assembl
howev
far
report
suggest
direct
effect
lovastatin
viral
protein
level
infect
cell
report
investig
whether
differ
avail
viral
structur
protein
nonstructur
protein
viru
assembl
follow
lovastatin
treatment
select
repres
viral
structur
protein
repres
nonstructur
protein
measur
viral
protein
level
reduct
level
either
protein
would
indic
direct
effect
viru
assembl
infect
howev
present
analysi
reveal
increas
viral
protein
level
follow
lovastatin
treatment
unexpect
suggest
although
viral
protein
readili
avail
abund
due
mechan
yet
identifi
rotavir
assembl
neg
affect
similar
effect
report
previous
rou
sarcoma
viru
infect
cell
treat
anoth
lipidreduc
agent
cerulenin
howev
case
underli
mechan
known
previou
studi
demonstr
associ
triplelay
infecti
rotaviru
virion
cellular
membraneassoci
lipid
raft
loss
associ
follow
treatment
cell
lipidlow
drug
far
report
demonstr
biochem
role
cholesterol
viral
entri
associ
viral
protein
infecti
virion
lipid
raft
none
conclus
provid
visual
demonstr
effect
lipidlow
drug
virion
assembl
contrast
current
studi
present
visual
evid
effect
cellular
lipidlow
drugmedi
perturb
rotaviru
biolog
relat
viru
assembl
